Pentoxifylline treatment prevented the reduction of fractional shortening and cardiac hypertrophy in vascular endothelial cell-specific endothelin-1 deficient mice subjected to transaortic constriction.
Does pentoxifylline improve cardiac function and hypertrophy in vascular endothelial ET-1 deficient mice subjected to chronic pressure overload?
Lack of endothelial ET-1 worsens pressure overload-induced cardiac dysfunction in mice, which can be prevented by pentoxifylline treatment through TNF-α-independent mechanisms.
Absolute Event Rate: 53.1% vs 48.4%
p-value: p=<0.05
BACKGROUND: Endothelin-1 participates in the pathophysiology of heart failure. The reasons for the lack of beneficial effect of endothelin antagonists in heart failure patients remain however speculative. The anti-apoptotic properties of ET-1 on cardiomyocytes could be a reasonable explanation. We therefore hypothesized that blocking the pro-apoptotic TNF-α pathway using pentoxifylline could prevent the deleterious effect of the lack of ET-1 in a model for heart failure. METHODS: We performed transaortic constriction (TAC) in vascular endothelial cells specific ET-1 deficient (VEETKO) and wild type (WT) mice (n = 5-9) and treated them with pentoxifylline for twelve weeks. RESULTS: TAC induced a cardiac hypertrophy in VEETKO and WT mice but a reduction of fractional shortening could be detected by echocardiography in VEETKO mice only. Cardiomyocyte diameter was significantly increased by TAC in VEETKO mice only. Pentoxifylline treatment prevented cardiac hypertrophy and reduction of fractional shortening in VEETKO mice but decreased fractional shortening in WT mice. Collagen deposition and number of apoptotic cells remained stable between the groups as did TNF-α, caspase-3 and caspase-8 messenger RNA expression levels. TAC surgery enhanced ANP, BNP and bcl2 expression. Pentoxifylline treatment reduced expression levels of BNP, bcl2 and bax. CONCLUSIONS: Lack of endothelial ET-1 worsened the impact of TAC-induced pressure overload on cardiac function, indicating the crucial role of ET-1 for normal cardiac function under stress. Moreover, we put in light a TNF-α-independent beneficial effect of pentoxifylline in the VEETKO mice suggesting a therapeutic potential for pentoxifylline in a subpopulation of heart failure patients at higher risk.
Heiden et al. (Tue,) conducted a other in Heart failure (chronic pressure overload) (n=85). Pentoxifylline vs. Untreated water was evaluated on Fractional shortening (%) in VEETKO mice after transaortic constriction (p=<0.05). Pentoxifylline treatment prevented the reduction of fractional shortening and cardiac hypertrophy in vascular endothelial cell-specific endothelin-1 deficient mice subjected to transaortic constriction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: